A phase 3, mulicenter, randomized, double-blind, placebo-controlled study to confirm the safety, tolerability and efficacy of zilucoplan in subjects with Generalized myasthenia gravis (RA Pharma 301: Raise)

Study RA101495-02.301 is a multicenter, randomized, double-blind, placebo-controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with gMG.

Sponsor(s)
UCB RA pharma
Principal Investigator(s)
Dr. Henry Kaminski
Contact Phone Number
Request Information
Address

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

1 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.